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Abstract
Although genetic and non-genetic studies in mouse and human implicate the CD40 pathway in rheumatoid arthritis
(RA), there are no approved drugs that inhibit CD40 signaling for clinical care in RA or any other disease. Here, we
sought to understand the biological consequences of a CD40 risk variant in RA discovered by a previous genome-wide
association study (GWAS) and to perform a high-throughput drug screen for modulators of CD40 signaling based on
human genetic findings. First, we fine-map the CD40 risk locus in 7,222 seropositive RA patients and 15,870 controls,
together with deep sequencing of CD40 coding exons in 500 RA cases and 650 controls, to identify a single SNP that
explains the entire signal of association (rs4810485, P=1.4 610
29). Second, we demonstrate that subjects homozygous
for the RA risk allele have ,33% more CD40 on the surface of primary human CD19+ B lymphocytes than subjects
homozygous for the non-risk allele (P=10
29), a finding corroborated by expression quantitative trait loci (eQTL) analysis
in peripheral blood mononuclear cells from 1,469 healthy control individuals. Third, we use retroviral shRNA infection to
perturb the amount of CD40 on the surface of a human B lymph o c y t ec e l ll i n e( B L 2 )a n do b s e r v ead i r e c tc o r r e l a t i o n
between amount of CD40 protein and phosphorylation of RelA (p65), a subunit of the NF-kB transcription factor. Finally,
we develop a high-throughput NF-kB luciferase reporter assay in BL2 cells activated with trimerized CD40 ligand
(tCD40L) and conduct an HTS of 1,982 chemical compounds and FDA–approved drugs. After a series of counter-screens
and testing in primary human CD19+ B cells, we identify 2 novel chemical inhibitors not previously implicated in
inflammation or CD40-mediated NF-kB signaling. Our study demonstrates proof-of-concept that human genetics can
be used to guide the development of phenotype-based, high-throughput small-molecule screens to identify potential
novel therapies in complex traits such as RA.
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Rheumatoid arthritis (RA) is a common autoimmune disease for
which there is no known cure. A diverse number of biological
pathways are altered in patients with RA, which impinge on a
wide-variety of cell types, tissue types and organ systems – innate
immune cells (e.g., neutrophils, dendritic cells, mast cells, platelets),
adaptive immune cells (e.g., B and T cells), bone, cartilage,
synovial fibroblasts, vascular cells, brain, muscle, and fat [1].
Accordingly, the task of sorting through which biological pathways
cause disease, as compared to those pathways that are simply a
consequence of disease, is a daunting challenge. Without knowing
the critical causal pathways, it is very difficult to develop novel
therapeutics to treat or cure RA.
There are fundamental principles of human genetics that make
it a promising strategy to identify critical biological pathways and
novel therapeutic targets in complex traits such as RA [2]. Since
risk alleles are randomly assigned at meiosis, are independent of
non-genetic confounding, and are unmodified by the disease itself,
human genetics can help distinguish between cause and conse-
quence. Moreover, risk alleles indicate if a pathway is up or down
regulated in disease – a critical first step in drug development. Risk
alleles help calibrate the amount of target modulation that is
tolerable in humans, as gain-of-function and loss-of-function
mutations in the same gene can be assessed for clinical phenotypes
in carriers of these mutations. Consistent with these concepts,
known drug targets that are safe and effective in humans appear
on the list of genes identified by genome-wide association studies
(GWAS) of common diseases [3], which suggests that other GWAS
hits represent targets worthy of further investigation [4].
However, there are important challenges in translating SNP
associations from human genetics (and GWAS in particular) to
novel therapeutics. First, the causal gene must be identified within
the risk locus, as there are often multiple genes in the region of
linkage disequilibrium. Compounding this challenge, most GWAS
hits are to non-coding variants that cannot pinpoint specific genes.
Second, the risk allele must be experimentally validated as gain- or
loss-of-function in a relevant human tissue, in order to guide
whether a drug should inhibit or activate (respectively) the target of
interest. Third, the biology of the risk allele should be recapitu-
lated in an assay system suitable for a high-throughput screen
(HTS). And fourth, the HTS should demonstrate performance
characteristics that make it robust for screening large chemical
libraries.
The CD40-CD40L pathway represents a good example of a
pathway for which human genetics may help guide drug
development. The pathway is upregulated in multiple diseases
[5–7], including autoimmune diseases such as RA [8–15]. GWAS
identified a common variant in the CD40 locus that increases risk
of RA, which suggests that CD40 upregulation is a cause rather
than a consequence of chronic inflammation [16]. Loss-of-function
mutations in both CD40 and CD40L result in immunodeficiency,
but only in the homozygous state, indicating that 50% inhibition
of CD40-CD40L signaling (as observed in heterozygous mutation
carriers) should be safely tolerated in humans [17].
Despite these findings, there are currently no approved drugs
that inhibit CD40-CD40L signaling, and there are no drugs in
clinical trials (www.clinicaltrials.gov). Others have developed small
molecules that disrupt CD40-CD40L binding, but these com-
pounds have not been tested in humans [18]. Antibodies to
CD40L were effective in treating inflammatory diseases, but
resulted in thrombotic events due to the presence of CD40L on
platelets [19–28]. Human genetics suggests that inhibiting
intracellular signaling of CD40-mediated signaling will also likely
be effective in humans, without adverse events related to
thrombosis.
Here, we demonstrate a strategy that uses findings from GWAS
to guide the development of a drug screen for the identification of
small molecules inhibiting the CD40-CD40L intracellular signal-
ing pathway. We hypothesize that such molecules might in turn be
safe and effective in treating inflammation observed in RA
patients. We set out (1) to investigate the biology of the CD40 risk
allele, by fine-mapping the CD40 locus and analyzing the function
of the risk allele in primary B cells from healthy donors; (2) to
recapitulate the biology of the CD40 risk allele in an assay system
suitable for a high-throughput screen (HTS) of small molecule
drugs; and (3) to conduct a pilot HTS to search for known and
novel inhibitors of CD40-mediated signaling in human B cells.
Results
The RA risk allele at CD40 locus induces an increase of
CD40 protein level on the surface of B cells
We first performed comprehensive genotyping at the CD40 risk
locus to fine-map the causal allele. Additional details can be found
in Text S1. We used a dataset in which RA case-control samples
were genotyped at high density across the CD40 locus with the
Illumina Immunochip platform (Eyre et al. Nat Genet. in press). In
total, we analyzed 492 SNPs in 7,222 seropositive RA patients and
15,870 controls (Table S1). As shown in Figure 1A, our analysis
revealed that the strongest signal of association was shared by 2
‘‘equivalent’’ non-coding SNPs in linkage disequilibrium (LD) at
r
2=0.98, rs6032662 and rs4810485 (P=1.4610
29, OR=1.17
per copy of the risk allele). After conditional analysis, no additional
signal of association remained, indicating that one of these 2 SNPs,
or one of the other six equivalent non-coding SNPs in LD at
r
2.0.80, is the underlying causal allele at this locus (Figure S1A,
Table S2A). We refer to rs4810485 as the index SNP; the major G
allele is the RA risk allele and the minor T allele is the non-risk
allele.
A previous study showed that a perfect proxy of the CD40 RA
risk allele increases CD40 protein on the surface of B lymphocyte
cells from 23 healthy individuals [29]. To confirm and extend
these findings, we developed a flow cytometry assay to measure
Author Summary
A current challenge in human genetics is to follow-up
‘‘hits’’ from genome-wide association studies (GWAS) to
guide drug discovery for complex traits. Previously, we
identified a common variant in the CD40 locus as
associated with risk of rheumatoid arthritis (RA). Here, we
fine-map the CD40 signal of association through a
combination of dense genotyping and exonic sequencing
in large patient collections. Further, we demonstrate that
the RA risk allele is a gain-of-function allele that increases
the amount of CD40 on the surface of primary human B
lymphocyte cells from healthy control individuals. Based
on these observations, we develop a high-throughput
assay to recapitulate the biology of the RA risk allele in a
system suitable for a small molecule drug screen. After a
series of primary screens and counter screens, we identify
small molecules that inhibit CD40-mediated NF-kB signal-
ing in human B cells. While this is only the first step
towards a more comprehensive effort to identify CD40-
specific inhibitors that may be used to treat RA, our study
demonstrates a successful strategy to progress from a
GWAS to a drug screen for complex traits such as RA.
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demonstrated high reproducibility of the assay on blood samples
drawn from the same individual .3 months apart (r
2=0.76,
Figure S2). We measured CD40 protein levels from 90 healthy
control subjects. We performed high-density SNP genotyping
across the CD40 locus, using the same genotyping array as in our
case-control study of RA risk. Strikingly, the strongest signal of
association across the CD40 locus was at the RA risk allele
(Figure 1B; P=3 610
29, Table S2). After conditional analysis, no
additional SNP was significant (Figure S1B). Healthy control
subjects homozygous for RA risk allele have ,33% more CD40
on the surface of primary human CD19+ B lymphocytes than
subjects homozygous for the non-risk allele (Figure 1C). The RA
risk allele (the G allele of rs4810485) explains 31% of variation
observed in CD40 protein level in these healthy control subjects,
and was the strongest signal among the genome-wide set of SNPs
tested for association with CD40 protein levels (Figure S1C).
To complement this finding, we examined CD40 gene
expression in peripheral blood mononuclear cells of 1,469
unrelated individuals [30]. As shown in Figure 1D, we found that
the RA risk allele was an expression quantitative trait locus (eQTL)
on CD40 gene expression (P=8.2610
213). Similar findings have
been reported for the RA risk allele in other immune cell types
[31,32].
Taken together, our data demonstrate unequivocally that the
RA risk allele (the G allele of rs4810485) is a gain-of-function
mutation that leads to increased level of CD40 on the surface of
primary human CD19+ B cells (and possibly other immune
lineages within PBMC’s).
CD40 influences p65 phosphorylation in a B-cell line
(BL2)
We next sought to determine the biological consequences of
having more CD40 on the surface of B cells, in order to determine
the most appropriate assay for a drug screen. Engagement of
CD40 by its trimerized ligand (tCD40L) leads to phosphorylation
of p65, a subunit of NF-kB (Figure 2A). To determine the effect of
p65 phosphorylation in a human B cell line (BL2) with varying
levels of CD40 protein, we derived clones in which CD40 mRNA
was knocked-down with shRNA [33]. In two independent cell
Figure 1. Genetic data on risk of RA and CD40 protein levels. (A) The regional association plot from analysis of Immunochip (iChip) data in
7,222 CCP+ cases and 15,870 controls. Gene location is shown along the bottom of the graph, with observed –log(P) value along the left Y-axis and
recombination rate along the right Y-axis. Each SNP is plotted is a circle, with color scheme (red to white) in reference to the extent of linkage
disequilibrium with the index SNP, rs4810485 (labeled as a diamond). (B) The regional association plot from analysis of iChip data and CD40 protein
levels in 90 healthy control individuals. (C) A box-whisker’s plot of SNP (rs4810485) and CD40 protein levels in B cells from healthy control individuals,
where T=non-risk allele and G=risk allele. (D) A box-whisker’s plot of SNP (rs4810485) and CD40 mRNA levels in PBMC’s from two separate
collections (total of 1,441 healthy control individuals); T=non-risk allele and G=risk allele.
doi:10.1371/journal.pgen.1003487.g001
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to the BL2 parent line, respectively (Figure 2B). We used the
parent BL2 line and two BL2/shRNA lines to activate the CD40
signaling pathway with tCD40L. In both BL2/shRNA cell lines,
we observed a reproducible decrease in phosphorylation of p65 at
Ser536 at 15 and 30 minutes following tCD40L activation. The
levels of NF-kB p65 phosphorylation, as measured by Western
blot, correlated with the levels of CD40 protein across all three B
cell lines (Figure 2C). That is, more CD40 on the surface of B cells
(as is the case for carriers of the RA risk allele) has increased
activation of the classical NF-kB pathway (as measured by
phosphorylation of NF-kB p65).
HTS to identify inhibitors of CD40-mediated NF-kB
signaling
A Western blot is not suitable for a high-throughput screen
(HTS). Based on our functional analysis, we developed a luciferase
reporter assay that can be used in an HTS to identify inhibitors of
CD40 signaling pathway. For this assay, we generated a BL2 cell
line (BL2-NFkB-Luc) that was transfected with a luciferase
reporter construct driven by a basal promoter element (TATA
box) joined to tandem repeats of the NF-kBr e s p o n s ee l e m e n t .
To optimize conditions for an HTS, we performed a series of
experiments with BL2-NFkB - L u cc e l l s .F i r s t ,w ep e r f o r m e da
titration of tCD40L, and found approximately 80% activation at
64 ng/ml tCD40L (Figure 2D). Second, we determined the
optimal time course following 64 ng/ml tCD40L activation, and
found maximum activation (5.6-fold induction) at 4.5 hours.
Third, we performed a titration of a known inhibitor of the
classical NF-kB signaling pathway, IKK inhibitor VII (Milipore)
(Figure 2E). To confirm that the decrease of NF-kB activity by
this inhibitor is not due to cytotoxicity, we used an anti-PARP
antibody (116-kDa poly-ADP-ribose nuclear polymerase) to
demonstrate by Western blot that the decrease in NF-kB
phosphorylation following IKK inhibition was not simply due to
cell death (Figure S3). And fourth, we determined the fold-
increase and fold-inhibition of luciferase activity following
tCD40L activation and IKK inhibition, respectively. We
observed robust performance of our assay under a specific set
of conditions (Figure 2F), with a Z’-factor<0.8 [34] (where a Z’-
factor of .0.50 is considered appropriate for a small-molecule
screen [35]).
Figure 2. CD40 knockdown and CD40-luciferase assay in BL2 cells. (A) Schematic of the canonical CD40 – NF-|B signaling pathway in B cells.
(B) RNAi perturbation of CD40 in two distinct clones derived from BL2 cells decreases CD40 protein levels by 55% (left) and 40% (middle) compared to
the BL2 parent line (black, right); (C) More CD40 on the surface of BL2 cells increases RelA (p65) phosphorylation following activation with tCD40L, as
measured by Western blot, with maximum activation at 15 minutes. Results are shown for the same two shRNA lines and parental BL2 cell line as in
(B). This is a representative example of multiple experiments. (D) Titration of tCD40L leads to increased luciferase activity. Each experiment was
performed in triplicate. The red circle represents ,80% maximum luciferase activity (64 ng/ml tCD40L). Luciferase activity at baseline (i.e., no tCD40L
activation) was subtracted from each measurement to plot results. (E) Titration of IKK inhibitor VII leads to inhibition of luciferase activity following
tCD40L activation. Each experiment was performed in duplicate. (F) The luciferase assay is robust, with Z’-factor.0.80 and .60-fold inhibition of
luciferase activity without killing cells across different plates.
doi:10.1371/journal.pgen.1003487.g002
GWAS to Small Molecule Screen of the CD40 Pathway
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conducted a pilot screen of 2,240 chemical compounds (of which
1,982 are in PubChem), each assayed in duplicate experiments.
The chemical compounds comprise bioactive compounds (includ-
ing FDA-approved drugs), commercially available drug-like
molecules, targeted collections (e.g., biased for kinases), stereo-
chemically-diverse compounds, and purified natural products.
Following normalization of luciferase activity to correct for
variability across plates, we determined fold-change in luciferase
activity relative to our positive (IKK inhibitor VII) and neutral
Figure 3. Small molecule screen of CD40-mediated NF-kB signaling in BL2 cells. (A) Results from duplicate experiments screening 1,982
compounds. Red circles are our positive control (IKK inhibitor VII); grey circles are our neutral controls (DMSO only); and blue circles are test
compounds. The red dashed line indicates .2SD from the mean of the neutral controls, which defines our ‘‘hit’’ compounds (n=81 compounds). (B)
Dose-response curves for two compounds known to inhibit inflammation [CID=5282230 (tranilast)] or NF-|B signaling [CID=5282360 (4-hydroxy-
estradiol)] in the BL2-NF|B-Luc cell lines. (C) Dose-response curves for two compounds not previously implicated in inflammation, NF-kB signaling,
CD40 signaling, or other biological pathways related to rheumatoid arthritis: CID=306804, [4-(1-acetyl-4-oxo-2H-3,1-benzoxazin-2-yl)phenyl] acetate;
and CID=7309015, 8-[(Z)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]-7-hydroxy-4-methylchromen-2-one. Red line=cells activated with tCD40L; black
line=cells activated with either CD40 or LPS (in BL2-TLR4-NFkB-Luc cells); green line=cell toxicity, as measured by CellTiter-Glo.
doi:10.1371/journal.pgen.1003487.g003
GWAS to Small Molecule Screen of the CD40 Pathway
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from 0.63–0.85 (average of 0.79). We observed strong correlation
between the two experimental replicates (r
2=0.94; Figure 3A).
We identified 81 compounds (4.1% of all compounds) with
.2SD decrease in luciferase activity relative to DMSO controls
(which we refer to as preliminary ‘‘hit’’ compounds; Table S3).
Even at this liberal threshold, there are more compounds that
decrease luciferase activity than would be expected by chance
alone (P=0.006). As further evidence that many of these hit
compounds represent true positive findings, we observed enrich-
ment of known anti-inflammatory agents using text-mining of
PubChem annotations [36,37] (Figure S5A–S5C) and enrichment
of shared chemical structure pertaining to corticosteroids and their
analogs (Figure S6 and Table S5), which are known NF-kB
inhibitors [38].
Confirmatory screens, counter-screens, and testing
compounds in primary CD19+ B cells
To confirm inhibition of CD40-mediated NF-kB signaling, we
conducted a series of counter-screens using our primary assay
(tCD40L-activated BL2-NFkB-Luc cells) and another B cell line,
Ramos RA-1, transfected with the same NF-kB luciferase reporter
construct (Ramos-NFkB-Luc). In addition to activation with
tCD40L, we activated BL2-NFkB-Luc cells with LPS (which
binds to TLR4 and signals through the classical NF-kB pathway)
and Ramos-NFkB-Luc cells with TNF-alpha (which also signals
through the classical NF-kB pathway). We measured luciferase
activity following exposure with each of the 73 compounds across
8 different concentrations (stock concentrations were not available
for 8 compounds). For 20 of the 73 compounds (,1% of all
compounds tested), we observed consistent, dose-dependent
inhibition across all four assays (BL2-NFkB-Luc cells activated
with tCD40 and LPS; Ramos-NFkB-Luc activated with tCD40L
and TNF-alpha), without evidence of cellular toxicity (Table S6).
To ensure that inhibition was due to effect of the chemical
compound and not an experimental artifact, we re-ordered 14 of
the compounds that were available commercially, confirmed
chemical structure and purity using high performance liquid
chromatography and mass spectrometry, and re-tested these
compounds using the same BL2- and Ramos-NFkB-Luc assays.
We confirmed that several compounds known to inhibit inflam-
mation (e.g., indoprofen; PubChem Compound ID [CID] 3718)
[39] or NF-kB signaling (e.g., 3-[(4-methoxyphenoxy)methyl]ben-
zohydrazide; CID 843208) [40] are potent inhibitors in our assays.
We also identified corticosteroids (e.g., 4-hydroxy-estradiol; CID
5282360) and inhibitors of inflammatory arthritis in murine
models of RA (tranilast; CID 5282230) [41,42]. Representative
examples are shown in Figure 3B and Figure S7.
Equally importantly, however, we identified 2 chemical
compounds not previously implicated in inflammation, NF-kB
signaling or inflammatory arthritis (Figure 3C and Figure 4). For
both, the relative IC50 was ,20 mM (Table 1), with .50%
decrease in luciferase activity (Table 2).
Finally, we tested 2 ‘‘known’’ and 2 ‘‘novel’’ compounds for
their ability to inhibit tCD40L-mediated NF-kB signaling in
primary CD19+ B cells from healthy control subjects. We used
flow cytometry to measure CD86 cell-surface protein levels, as
CD86 expression is up-regulated upon activation of B cells with
CD40L [43]. We observed dose-dependent decrease in CD86
expression with all 4 compounds (Figure 4). Thus, we confirmed
that the 2 known inhibitors and the 2 novel compounds identified
in our HTS inhibit the NF-kB signaling pathway in primary
CD19+ B cells from healthy donors.
Discussion
Our study exploits fundamental principles of human genetics to
guide a small molecule drug screen in RA. We show that
upregulation of the CD40-CD40L signaling pathway is a cause
rather than a consequence of disease, as the RA risk allele
increases levels of CD40 on the surface of B lymphocyte cells and
increases CD40-mediated NF-kB signaling. Based on our genetic
findings, a prediction is that drugs that attenuate CD40-mediated
NF-kB signaling will either protect from RA or treat symptoms in
patients with active disease. From our screen, we identify two
compounds that support this hypothesis: tranilast, which reduces
inflammation in a mouse model of RA [41], and a corticosteroid,
which is a potent anti-inflammatory drug used to treat RA [44,45].
Equally important, we discover 2 novel small-molecules that
inhibit CD40 signaling through the classical NF-kB pathway in
primary CD19+ B cells.
There are few examples where GWAS was used to guide drug
discovery. One example is PCSK9, where a loss-of-function variant
is associated with lower levels of LDL cholesterol and protection
from cardiovascular disease [46–49]. However, the original
finding implicating PCSK9 and LDL cholesterol came not from
GWAS, but from sequencing in families with autosomal dominant
high LDL levels and an increased incidence of coronary heart
disease [50]. In 2012, a randomized control trial was published
that a monoclonal antibody to PCSK9 significantly reduced LDL
cholesterol levels in healthy volunteers and in subjects with
hypercholesterolemia [51,52]. Another example is BCL11A and
persistence of fetal hemoglobin in sickle cell anemia. In 2008, a
GWAS found an association with a common, non-coding variant
of the hemoglobin silencing factor gene, BCL11A, and HbF
expression [53,54]. Based on these data, together with data from
animal models [55], repressors of BCL11A are under development
for the treatment of sickle cell disease [56].
Our study illustrates another example, as we demonstrate that
genetic findings can be instrumental in developing optimal high-
throughput drug screens. In RA, many biological pathways have
been implicated. Consequently, identifying relevant pathways is
critical for the development of molecules that will be effective in
treating the disease. Our strategy successfully links an RA risk
allele to a biological process suitable for an HTS. First, we show
unequivocally that the RA risk allele leads to increased levels of
CD40 protein on the surface of CD19+ B cells, thereby
establishing a causal link between increased CD40 protein levels
and risk of RA. Second, we establish a direct relationship between
amount of CD40 on the surface of B cells and an intracellular
biological pathway, NF-kB signaling. In doing so, we recapitulate
the effect of the CD40 risk allele in an assay system suitable for an
HTS.
There are important limitations of our study. First, the chemical
library tested in our study is small relative to libraries in academic
centers and industry (which often contain hundreds of thousands
to millions of compounds) [57,58]. Second, our screen did not
identify inhibitors specific to CD40 signaling. Whether a more
selective CD40 inhibitor would be a better therapeutic than a
more general inhibitor requires additional studies. That our HTS
identified two ‘‘known’’ drugs that inhibit inflammation reinforces
that our general strategy is successful. Third, we have not yet
tested our compounds in animal models of RA. However, one of
our known compounds, tranilast, has been shown by others to
inhibit collagen-induced arthritis in the mouse [41]. Fourth, we do
not yet know the target of our ‘‘novel’’ small molecule inhibitors of
CD40-mediated NF-kB signaling. One of these compounds (CID
7309015) has been annotated in PubChem as an inhibitor of
GWAS to Small Molecule Screen of the CD40 Pathway
PLOS Genetics | www.plosgenetics.org 6 May 2013 | Volume 9 | Issue 5 | e1003487Figure 4. Effect of compounds on CD86 expression in primary CD19+ B cells. Purified human CD19+ primary B cells were incubated with
10 ng/ml IL4 alone (‘‘No activation’’) or IL4+64 ng/ml tCD40L (‘‘Activation’’), together with different concentrations of drugs for 48 hours. CD86
expression was measured by PE GeoMFI on CD19+ gated B cells. The chemical structure of each compound is shown.
doi:10.1371/journal.pgen.1003487.g004
Table 1. Relative IC50 for two ‘‘known’’ and two ‘‘novel’’
compounds in both BL2-NFkB-Luc and Ramos-NFkB-Luc cell
lines.
BL2/
tCD40L
BL2-TLR4/
LPS
Ramos/
tCD40L
Ramos/
TNFa
‘‘known’’ compounds
5282230 3.8 6.3 7.1 8.1
5282360 4.1 1.8 2.1 1.3
‘‘novel’’ compounds
306804 2.5 1.6 9.4 6.7
7309015 5.0 3.0 18.3 16.4
Relative IC50 is the concentration required to bring the dose-response curve to
the halfway point between the top and bottom plateaus of the curve.
doi:10.1371/journal.pgen.1003487.t001
Table 2. Percent maximum inhibition for two ‘‘known’’ and
two ‘‘novel’’ compounds in both BL2-NFkB-Luc and Ramos-
NFkB-Luc cell lines.
BL2/tCD40L
BL2-TLR4/
LPS
Ramos/
tCD40L
Ramos/
TNFa
‘‘known’’ compounds
5282230 54.7% 73.7% 86.4% 87.4%
5282360 87.0% 54.1% 95.1% 92.7%
‘‘novel’’ compounds
306804 83.8% 51.8% 91.7% 90.5%
7309015 90.2% 63.3% 78.3% 85.7%
For each compound, we calculate the maximum amount of inhibition observed
at the highest concentration of drug relative to zero luciferase activity.
doi:10.1371/journal.pgen.1003487.t002
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tion factor that has a central role in the differentiation of CD4+
Th17 cells. However, this PubChem annotation has not yet been
linked to a PubMed manuscript. The other compound has not
been confirmed as active in any PubChem assay, and therefore
represents a novel tool compound for further study.
In conclusion, we demonstrate a strategy to translate GWAS
findings into HTS to identify novel small-molecule inhibitors of
the CD40 signaling pathway. Given the wealth of GWAS data
that has accumulated in recent years, human genetics represents a
promising approach to develop safe and effective therapies to treat
complex human diseases such as RA.
Materials and Methods
Our study was approved by the institutional review board (IRB)
at our institutions.
Genetic analysis of CD40 risk locus in RA case-control
samples
Six case-control collections were included for genotyping using
the Illumina Immunochip platform (Table S1), as part of the
RACI consortium [59]; the GWAS datasets have been previously
described, and include 4 collections that did not overlap with the
Immunochip dataset [60]. All six Immunochip datasets were
clustered together using the Illumina Genome Studio algorithm.
Initial data filtering steps in GenomeStudio included: removal of
samples with call rate,90% and removal of SNPs with poor
clustering quality metrics (call frequency,0.98, cluster separa-
tion,0.4). Further quality control was performed in the six
individual population datasets separately. First, samples with call
rate ,99% were excluded. Second, SNPs with call rate ,99% in
either the RA cases or controls were excluded. To address
population stratification, we selected a set of common SNPs
(MAF.5%), pruned to remove SNPs in LD. We calculated
pairwise identity-by-state (IBS) statistics using PLINK [61], and
removed one individual from each pair of individuals who were
2
nd degree or closer relatives. Principal components analysis (PCA)
was subsequently performed using EIGENSTRAT [62]. After
exclusion of individuals of non-European ancestry, as determined
by clustering with CEU HapMap (phase II), a second PCA was
performed to further remove outliers. Cases with anti-CCP
negative or missing anti-CCP status data were removed, leaving
7,222 CCP+ cases and 15,870 controls for association analysis. To
avoid duplicate samples, we used IBS estimates to remove related
samples between the Immunochip and GWAS collections.
Specifically, we selected a set of genotyped SNPs with missing-
genotype rate,0.5%, MAF .5% and Hardy-Weinberg equilib-
rium (HWE) P.10
23 that were shared across all 10 collections.
When related samples were identified (siblings or duplicates), the
sample from the GWAS data was removed (to preferentially keep
genotyped data rather than imputed data in the subsequent
association analyses), bringing the total sample size to 9,785
seropositive RA cases and 33,742 controls (Table S1). Finally, we
computed a chi-square test to assess the difference in missingness
between cases and controls and removed SNPs with a Pmiss-
ing,10
22, together with SNPs in departure form Hardy-Weinberg
equilibrium (PHWE.5.7610
27).
To test for association with risk of RA, we used PLINK to
conduct logistic regression analysis of the six Immunochip RA
case-control status, including 10 eigenvectors as covariates. We
conducted an inverse-variance weighted meta-analysis to combine
the results across the 6 collections, for the 156,520 SNPs across the
genome with results in one or more collections, including 492
SNPs across the CD40 locus. We also computed Cochran’s Q
statistic and I
2 statistic to assess heterogeneity across collections.
Meta-analysis and heterogeneity statistics computation was
adapted from the MANTEL program.
Sequence data at the CD40 locus was generated as part of a
larger experiment to perform pooled sequencing of 25 RA risk
genes (Supplementary Material). Using Syzygy (a pooled variant
caller) [63], we estimated the allele frequencies in the overall
sample set (500 cases and 650 controls of European ancestry
geographically and genetically matched). We observed a strong
correlation between genotype frequencies available from our
GWAS data and frequencies estimated using the method in
Syzygy indicating accurate experimental recovery of the pool
composition. For the CD40 region, we had no coverage of exon 1,
but near complete coverage of the remaining eight exons (Figure
S4). After stringent quality control (Supplementary Material), we
observed 4 coding variants at the CD40 locus: two coding-
synonymous SNPs and two missense SNPs. None of the SNPs was
associated with RA either in a single-SNP analysis or in a gene-
burden test (Table S2B).
Measurement and genetic analysis of CD40 levels
CD40 protein levels on the surface of unstimulated CD19
+ B
cells were measured in healthy control subjects from the
PhenoGenetic Project of Brigham and Women’s Hospital, a living
biobank of 1,739 subjects free of chronic inflammatory and
infectious diseases recruited from the general population of
Boston, MA. Subjects used in this experiment were randomly
selected from the biobank. Fresh PBMCs were isolated from 10 ml
blood with 5 ml Ficoll-Hypaque (GE; Cat#07908). PBMCs were
washed once in 0.1%BSA/PBS and blocked with FcR blocking
reagent (Milteyi Biotec; Cat.#120-000-442). After red blood cells
were lysed in 10 ml human red blood cell lysis buffer, 0.25610
6
isolated PBMCs were double-labeled with an anti-CD19-FITC
(eBioscience; Cat.#11-0199-73) and anti-hCD40/TNFRSF5-PE
(R&D; Cat.#FAB6321P). The CD40 levels were measured by
FACS analysis with PE-GeoMFI on CD19
+ cells. As a negative
control, an anti-IgG2B-PE (R&D; Cat.#IC0041P) was used; in
addition, we used frozen BL2 cells to normalize for day-to-day
variation. In total, 97 subjects had both CD40 protein levels
measured and genotyping generated using the Immunochip
beadset at Yale University. The same initial data-filtering steps
described above were performed. Following QC, 90 samples with
a call rates .99% were included in the analysis. After HapMap
phase III PCA, no sample was removed based on ethnicity. A
second PCA was performed to compute eigenvectors to include in
the association analysis. We conducted a linear regression analysis
to test for CD40 protein level-SNP association (PLINK). Ten
eigenvectors were included as covariates in the linear model.
Details of the eQTL analysis have been previously described
[30]. In short, we assessed the effect of rs4810485 on CD40 in
whole peripheral blood in a collection of 1,469 samples (1,240
samples run on the Illumina HT12v3 platform, 229 samples run
on the Illumina H8v2 platform). We used a Spearman rank
correlation and meta-analysis using a weighted Z-method to
calculate statistical significance of the rs4810485 G alleles CD40
gene expression levels.
BL2 cells and shRNA targeting of CD40
BL2 cells were purchased from DSMZ (Germany; Cat.# ACC
625). Both BL2/shRNA cell line and BL2-NFkB-Luc cell line
were derived from BL2 cells, as described below. All cells were
cultured in RPMI 1640 medium (Life Technologies, Inc)
supplemented with 10% FBS. For CD40 activation, cells were
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ligand (tCD40L). Two independent BL2 cell lines were generated,
in which CD40 was knocked-down using a HuSH shRNA Plasmid,
pGFP-V-RS (Origene; Cat.# TR30007). A double-stranded DNA
oligo containing a hairpin structure with sequence specific to
human CD40 gene (sequence below) [33] was cloned into the
pGFP-V-RS, according to manufacture specifications (Origene).
59GATCGGCGAATTCCTAGACACCTGTTTCAAGAGA-
ACAGGTGTCTAGGAATTCGCTTTTTTGAAGCT39
The plasmid (20 mg) was linearized by ScaI and cotransfected
into BL2 cells with a puromycin selection vector by electropora-
tion at 300 V and 950 mF. Transfected cells were cultured in
regular medium for 2 hours before they were serially diluted and
plated into 96-well plates. For selection, cells were grown in
0.3 mg/ml puromycin. Single colonies were picked two weeks later
and CD40 levels were measured by Western blot and FACS
analysis.
Analysis of p65 phosphorylation
For the immunoblot detection, 0.25610
6 BL2 cells were
activated either with or without tCD40L. Whole-cell lysate was
prepared with 10 ml RIPA buffer and then subjected to
electrophoresis on a 7.5% SDS-PAGE gel under reducing
conditions. Proteins were electro-blotted onto a nitrocellulose
membrane. The membranes were detected by antibodies for
CD40 (Santa Cruz; cat#: sc-13128), NF-kB p65 (Cell signaling;
cat#: 4767) and phospho-NF-kB p65 (Ser536) (Cell signaling;
cat#: 3033).
Luciferase assay to detect the activity of NF-kB in BL2
and Ramos cells
A cignal lenti luciferase reporter construct driven by a basal
promoter element (TATA box) joined to tandem repeats of the NF-
kB response element was infected into BL2 and Ramos RA-1 cells,
according to manufacture specifications (Qiagen; Cat.# CLS-
013L). We call these two lines as BL2-NFkB-luc and Ramos-NFkB-
luc, respectively. Single colonies were selected on 96 well plates with
0.3 mg/ml puromycin. Positive clones were further screened by
luciferase assay with Steady-Glo assay system (Promega) after 4 hr
activation by 64 ng/ml tCD40L. Since the expression of luciferase
gene is controlled by the activity of NF-kB, we were able to measure
the activity of NF-kB following activation with tCD40L by
measuring the activity of luciferase. For LPS activation in BL2
cells, a BL2-NFkB-luc line was transfected with episomal DNA of
TLR4 (pUNO1-hTLR4a, InvivoGen) for high levels of TLR4
expression. We call this line as BL2-TLR4-NFkB-luc.
High-throughput screen for inhibitors and activators for
CD40 signaling pathway
The high-throughput screening assay was optimized in 384-well
format in collaboration with the Broad Institute Probe Develop-
ment Center (BIPDeC). Briefly, 10 mL BL2-NFkB-luc cells at 25K
cells/well were plated into each well on a 384-well plate (Perkin
Elmer; Cat.# 6008230) using a Multidrop Combi dispenser
(Thermo). For each compound, DMSO or positive control IKK
inhibitor VII, 25 nL was transferred using a pin tool (Cybio). The
final concentration for each compound was 9.4 mM; DMSO
0.25%; and IKK inhibitor VII 50 mM. After cells were incubated
at 37uC for 1 hour, 10 uL (192 ng/mL) tCD40L was added to
make a final concentration of 64 ng/ml. Cells were incubated at
37uC for 4.5 hrs before 5 uL 1X Steady-Glo luciferase substrate
was added. Luciferase activity was read after 5 min using LJL
analyst plate reader (LJL BioSystems). Each compound was tested
in duplicate. A complete list of the compounds can be found in
Table S3. We refer to this set of compounds as our ‘‘2K screening’’
set.
Seventy-three of 81 ‘‘hit’’ compounds from the primary screen
were advanced into a series of counter-screens. The 73 compounds
were selected because stock concentrations of each compound
were available for dose-titration experiments. Each compound was
tested across a range of concentrations from 50 mM to 0.39 mM (2-
fold decrease between doses). In addition to screening BL2-NFkB-
luc cells activated with tCD40L, we also screened BL2-TLR4-
NFkB-luc cells activated with 16 ng/ml LPS (Sigma). We screened
an additional B cell line transfected with the same luciferase
reporter contruct, Ramos-NFkB-luc cells, and activated with
64 ng/ml tCD40L and 64 ng/ml TNFa (eBioscience). Cell
viability of both lines was evaluated by adding 5 ul 0.5X
CellTiter-glo.
Measurement of CD86 expression in human CD19+
primary B cells
CD86 protein levels were measured in human primary CD19+
B cells from the PhenoGenetic Project purified by MACs (Milteyi
Biotec; Cat# 130-091-151). Purified human primary CD19+ B
cells (1610
6) were pre-incubated with 10 ng/ml IL4 and different
concentrations of drugs in each well of a 24-well plate at 37uC for
one hour. Cells were activated with and without 64 ng/ml
tCD40L. After 48 hours, cells were stained with anti-CD19-
FITC/anti-CD86-PE (Biolengd; Cat#305405). CD86 expression
was measured by PE GeoMFI on CD19+ gated B cells.
Statistical analysis of compound screening data
The raw signals of each 384-well microtiter wells were
normalized using the ‘‘Neutral Controls minus Inhibitors’’ method
in Genedata Assay Analyzer (v7.0.3). The median raw signal of the
intraplate neutral-control wells was set to a normalized activity
value of 0. The median raw signal of the intraplate positive-control
wells was set to a normalized absolute activity value of 100. The
plate pattern correction algorithm ‘‘Assay Median’’ in Genedata
(v7.0.3) was applied to the normalized plate data. We used DMSO
neutral controls to define 95% confidence intervals (CI) of our 2K
screening compounds. We defined ‘‘hits’’ as those compounds
outside of 95% CI in both dimensions of the replicate experiments.
This led to 86 compounds that inhibited luciferase activity,
consistent with our positive IKK inhibitor control. We defined a
compound as promiscuous if it satisfies both of the following two
rules: (1) the number of assays in which it has been tested is larger
than 50, and (2) the ratio between the number of hits and the
number of assays in which it has been screened is larger than 0.25.
Based on these criteria, we found 40 promiscuous compounds, 5 of
which had .2SD inhibition of luciferase activity, yielding 81
compounds that inhibited luciferase activity. A list of all
compounds tested, including the annotation of 40 promiscuous
compounds, can be found in Tables S3 and S4.
To calculate relative IC50, the nls function in the R package of
stats (2.14 version) was used to fit the four-parameter logistic non-
linear regression model as follows. This method represents the
nonlinear (weighted) least-squares estimates of the parameters of a
nonlinear model, with the equation (xn is concentration and yn is
luciferase intensity): yn*Lzh=(1ze{((xn{a)=b)). It estimates the
four parameters L, h, a, and b. The starting point of L is the
maximum value at smallest concentration; the starting point of h is
the minimum difference between the minimum value at the largest
concentration and the average value at smallest concentration.
The starting point of a and b are 4 and 2, respectively. The R
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the curves. In some cases where a singular gradient happens, the
parameters are not estimable; when a plateau was not observed,
the curve was smoothed by loess.smooth function in R and the
percentage was calculated by the observed values. The 95%
confidence interval (CI) was computed based on the observed data
and transferred into percentage. To calculate percent maximum
inhibition for each compound, we determined the difference
between the average activity at the lowest drug concentration and
the average activity at the highest drug concentration. The percent
maximum inhibition was then obtained by dividing the difference
by the average activity at the lowest drug concentration.
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conditional analysis of rs4810485 in (A) case-control study of RA
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(i) we used text-mining to annotate each compound with a
‘‘Pharmacological Action’’ MeSH term in PubChem; each
Pharmacological Action term set contains multiple compounds;
(ii) for each compound, we determine luciferase activity relative to
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distribution of compounds within each term set relative to the
entire distribution of results. (B) The distribution of enrichment
scores for 117 groups of pharmacological action terms with $3
compounds. Red indicates positive enrichment and blue indicates
negative enrichment relative to all sets tested. The dashed line
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compound sets that surpass this level of significance are labeled.
(C) The results of top 5 compound sets from the enrichment
analysis. Each strip shows the distribution of all results, with black
lines indicating specific compounds within each set. The top 5
compound sets are shown, with the number of compounds that
inhibit luciferase activity, total number of compounds with the
specific Pharmacological Action term annotation, and P-value for
enrichment shown at the top (from the Wilcoxon mean rank test).
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Figure S6 Corticosteroid compounds and chemical structure.
(A) Core structures of the corticosteroid hits. Chemical similarity of
28 corticosteroids and their analogs. Since there are only 45
corticosteroids among 1,982 compounds tested, this finding
represents a significant enrichment among hits (P,10
216). (B)
Functional groups of the corticosteroid hits that create rings.
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Figure S7 Dose-response curves for two ‘‘known’’ and ‘‘un-
known’’ compounds in Ramos-NFkB-Luc cells.
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